Use of Administrative Claims Data to Estimate Treatment Effects for 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Findings From the EXTEND-DAPT Study

被引：10
|
作者：
Faridi, Kamil F. [1 ,2 ]
Tamez, Hector [2 ]
Strom, Jordan B. [2 ]
Song, Yang [4 ]
Butala, Neel M. [3 ]
Shen, Changyu [2 ]
Secemsky, Eric A. [2 ]
Mauri, Laura [4 ,5 ]
Curtis, Jeptha P. [1 ]
Gibson, C. Michael [2 ,4 ]
Yeh, Robert W. [2 ,3 ,4 ]
机构：
[1] Yale Sch Med, Sect Cardiovasc Med, Dept Med, New Haven, CT USA
[2] Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Richard A & Susan F Smith Ctr Outcomes Res Cardio, Boston, MA 02215 USA
[3] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Cardiol Div, Boston, MA 02115 USA
[4] Baim Inst Clin Res, Boston, MA USA
[5] Medtronic, Minneapolis, MN USA
来源：
CIRCULATION | 2020年 / 142卷 / 03期
关键词：
administrative claims; healthcare; clinical trial; coronary artery disease;
D O I：
10.1161/CIRCULATIONAHA.120.047729
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：306 / 308
页数：3
相关论文
共 50 条
  • [41] Risk/Benefit Tradeoff of Prolonging Dual Antiplatelet Therapy More Than 12 Months in TWILIGHT-Like High-Risk Patients After Complex Percutaneous Coronary Intervention
    Wang, Hao-Yu
    Dou, Ke-Fei
    Yin, Dong
    Xu, Bo
    Zhang, Dong
    Gao, Run-Lin
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 133 : 61 - 70
  • [42] Efficacy and safety of short-term 1-3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials
    Zhang, Wen-Jiao
    Qiao, Xuan
    Liang, Xi-Ying
    Li, Yan
    Yang, Rong-Rong
    Wang, Zhi-Lu
    PLATELETS, 2021, 32 (05) : 582 - 590
  • [43] Six Versus Twelve Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention With Biodegradable Polymer Sirolimus-Eluting Stents for Bifurcation Lesions: Insights From the I-LOVE-IT 2 Trial
    Xu, Bo
    Guan, Changdong
    Xu, Kai
    Jing, Quanmin
    Yang, Yuejin
    Han, Yaling
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2015, 66 (15) : B35 - B36
  • [44] DAPT Study Investigators. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention (vol 315, pg 1735, 2016)
    Yeh, R. W.
    Secemsky, E. A.
    Kereiakes, D. J.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2016, 316 (03): : 350 - 350
  • [45] Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals
    Yokoi, Hiroyoshi
    Oda, Eisei
    Kaneko, Kazuki
    Matsubayashi, Kenta
    CARDIOVASCULAR INTERVENTION AND THERAPEUTICS, 2022, 37 (03) : 465 - 474
  • [46] Duration and clinical outcome of dual antiplatelet therapy after percutaneous coronary intervention: a retrospective cohort study using a medical information database from Japanese hospitals
    Hiroyoshi Yokoi
    Eisei Oda
    Kazuki Kaneko
    Kenta Matsubayashi
    Cardiovascular Intervention and Therapeutics, 2022, 37 : 465 - 474
  • [47] Ischaemic and bleeding outcomes in elderly patients undergoing a prolonged versus shortened duration of dual antiplatelet therapy after percutaneous coronary intervention: insights from the PRODIGY randomised trial
    Piccolo, Raffaele
    Magnani, Giulia
    Ariotti, Sara
    Gargiulo, Giuseppe
    Marino, Marcello
    Santucci, Andrea
    Franzone, Anna
    Tebaldi, Matteo
    Heg, Dik
    Windecker, Stephan
    Valgimigli, Marco
    EUROINTERVENTION, 2017, 13 (01) : 78 - 86
  • [48] Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial
    Jingen Li
    Jianqing Ju
    Zhuo Chen
    Jing Liu
    Fang Lu
    Rui Gao
    Hao Xu
    Trials, 19
  • [49] Guanxinning tablet for patients who switch from dual antiplatelet therapy to aspirin alone after percutaneous coronary intervention: study protocol for a cluster randomized controlled trial
    Li, Jingen
    Ju, Jianqing
    Chen, Zhuo
    Liu, Jing
    Lu, Fang
    Gao, Rui
    Xu, Hao
    TRIALS, 2018, 19
  • [50] Clinical Outcomes Of P2Y12 Inhibitor Monotherapy Versus Dual Antiplatelet Therapy After Percutaneous Coronary Intervention In Patients With Acute Coronary Syndrome: A Meta-Analysis Of Randomized Controlled Trials
    Gupta, Soumya
    Thakkar, Aditya
    Aggarwal, Devika
    Bhatia, Kirtipal
    Choi, James
    Carter, Kristen
    Kaur, Arpanjeet
    Casso, Abel
    CIRCULATION, 2024, 150
12345